Immunic Inc Corporate Update Transcript
Good morning, everyone. I would like to welcome you to Immunic's CALDOSE-1 top line data and corporate update webcast. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call. Speaking on the webcast are our Chief Executive Officer and President, Dr. Daniel Vitt; our Chief Medical Officer, Dr. Andreas Muehler; and our Chief Scientific Officer, Dr. Hella Kohlhof.
(Operator Instructions) And this event is being recorded. The purpose of today's webcast is to discuss the top line data from our Phase II CALDOSE-1 trial of vidofludimus calcium in patients with moderate to severe ulcerative colitis. In the second part of the webcast, we will provide a corporate update. (Operator Instructions)
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with a similar meaning; and such statements involves a number of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
